Background: The early detection of acute kidney injury (AKI) in patients with
mortality and treatment costs. [5] [6] [7] Hence, the accurate early detection of AKI is an unmet clinical need. The novel biomarker Proenkephalin (PENK) is a stable fragment derived from the precursor enkephalins, which are known as small endogenous opioid peptides and are produced throughout the human body, including the kidneys. 8 Spot measurements of PENK were recently shown to reflect renal function in healthy subjects, and elevated levels are independently associated with an accelerated decline in renal function and a progression to chronic kidney disease. 9 However, PENK is a dynamic parameter and its levels can significantly change within hours. For example, a small pilot study recently showed PENK levels to increase within 6 hours after cardiac surgery in patients experiencing postsurgical AKI, while simultaneously measured serum creatinine levels showed a delayed increase. 10 Hence, these data suggest that PENK levels might improve the early detection of AKI. 10, 11 These previous studies predominantly included patients with preserved renal function, despite chronic kidney disease (CKD) being a powerful risk factor for the development of AKI. 12, 13 Hence, any biomarker aiming to improve the early detection of AKI in clinical practice needs to retain its diagnostic potential in the vulnerable CKD patient population. We therefore aimed to examine the potential of PENK levels to improve the early detection of AKI over the current clinical gold standard of serial serum creatinine sampling in hospitalized CKD patients.
| METHODS
This study uses prospectively collected plasma obtained in a multicenter, randomized, open-label, controlled trial (Clinicaltrials.gov Identifier: NCT00130598) that compared two regimens of sodium bicarbonate vs standard volume supplementation with isotonic sodium chloride in the prevention of contrast-induced AKI in hospitalized patients with chronic renal dysfunction. The study was conducted between March 2005 and December 2009, and its details have been described before. 14 In short, renal dysfunction was defined as serum creatinine level >93 μmol/L for women and >117 μmol/L for men or an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 (assessed 24 hours before the radiographic procedure).
Patients were excluded if they were <18 years old, pregnant, or allergic to radiographic contrast, were undergoing dialysis, had severe heart failure (NYHA III-IV), had taken N-acetylcysteine ≤24 hours before CM administration, or suffered from a vulnerable condition requiring continuous fluid therapy (eg, severe sepsis). For this study, only patients with complete baseline-day 1 plasma sample pairs were included. The study was conducted according to the principles of the revised Declaration of Helsinki had been approved by the local ethical committees, and all participants gave written informed consent for the study. The authors designed the study, gathered, analysed and report the data according to the STARD guidelines for studies of diagnostic accuracy (Table S1 ) and made the decision to submit it for publication. TB, CJ and CM had full access to all of the data in the study and vouch for the accuracy and completeness of the data, the analysis, and the presentation, take responsibility for the integrity of the data and the accuracy of the data analysis. TB and CM wrote the first draft of the manuscript.
| Biomarker measurements
Plasma samples were prospectively collected at baseline and Day 1. After centrifugation, samples were frozen at −80°C until assayed in a blinded fashion in a single batch. The assay for stable PENK (molecular weight 4586 Da) was previously described 15 and has since been modified 16 (sphingotest ® penKid). In brief, two mouse monoclonal anti-PENK antibodies were developed by immunization with PENK peptide. Standards or samples (50 μL plasma) were immobilized by the capture antibody (2 μg coated on polystyrene tubes). The detector antibody was labelled with methylacridinium ester, and bound chemiluminescence was measured. The normal range was mean ± SEM of 46.6 ± 14.1 pmol/L, with a median of 45 pmol/L (range 9-518 pmol/L). 15 Creatinine measurements were performed on a Roche Modular P1 analyzer with the enzymatic Creatinine-PAP method for quantification (Roche Diagnostics, Rotkreuz, Switzerland). The estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease Study (MDRD) equation. 17 
| Endpoint
The ability of PENK levels to detect the occurrence of contrast-induced AKI was assessed as the primary endpoint. Development of contrast-induced AKI was defined as a serum creatinine increase of ≥25% or an increase of ≥44 μmol/L over the baseline serum creatinine concentration within the first 48 hours after CM administration. 14, 18 Creatinine-blind AKI was defined as AKI occurring between day 1 and day 2, that is not detectable by creatinine at day 1. Creatinine-blind AKI was considered as a secondary endpoint.
| Statistical analysis
The statistical analyses were performed using the SPSS/PC 3 | RESULTS
| Study population
A patient flow chart for the current study is displayed in Figure 1 . Detailed characteristics of study population are summarized in Table 1 . The median age of the 111 patients was 77 years (IQR 72-80). Most patients had stage 3 CKD with a median eGFR at baseline of 45 mL/ min/1.73 m 2 (IQR 38-50). Hypertensive nephropathy was the main aetiology of CKD (41%), followed by combined hypertensive and diabetic nephropathy (26%) and other not further specified nephropathies (18%). The majority of patients underwent either computer tomography scans (50%) or cardiac catheterization with (17%) or without PCI (21%). A median of 100 ml of CM (IQR 70-140) was administered during contrast procedures. Overall, 7 of 111 patients (6%) developed contrast-induced AKI.
| Baseline Proenkephalin levels
Baseline PENK levels were moderately correlated to baseline creatinine (r = 0.27; P < 0.01), heart rate (r = 0.22; P = 0.02) and body mass index (r = −0.23; P = 0.02), but not to age (P = 0.18) and systolic blood pressure (P = 0.31). The median PENK level in the overall patient population was 126 pmol/L [IQR: 100-166] and 97 patients (87%) displayed PENK levels above the upper limit of normal (80 pmol/L); 80 patients (75%) displayed PENK levels above 100 pmol/L. As shown in Table 1 
| Proenkephalin levels for the prediction of creatinine-blind AKI

| Delta Proenkephalin for the prediction of contrast-induced AKI
In the overall patient population, there was no change between baseline and day 1 PENK levels (median change: 2.23 pmol/L, P = 0.47). However, delta PENK was Figure 2C ). Delta PENK was moderately correlated to the maximal serum 48 h creatinine increase (r = 0.24, P = 0.01) but not to baseline PENK (P = 0.09), or baseline serum creatinine (P = 0.61). To evaluate the potential of delta PENK to predict the occurrence of AKI, ROC analyses were performed. The AUC for the prediction of AKI by delta PENK was high: 0.92, 95% CI: 0.82-1.00 ( Figure 3) . In a secondary analysis, which applied the serum criteria of the KDIGO AKI classification delta PENK achieved a similar AUC (0.93, 95% CI: 0.84-1.00) for the prediction of contrast-induced KDIGO AKI. When restricting the analysis to creatinine-blind AKI cases, occurring between day 1 and day 2, delta serum creatinine only achieved a moderate AUC (AUC 0.65, 95% CI: 0.23-1.00).
In contrast, the predictive potential of delta PENK for creatinine-blind AKI (AUC 0.94, 95% CI: 0.87-0.97) remained high. When entering the biomarkers into a univariate binary regression analysis, delta creatinine (OR per standard deviation increase: 15.78, 95% CI: 2.88-86.58; P < 0.01) and delta PENK (OR per standard deviation increase: 6.60, 95% CI: 2.25-19.35; P = 0.01) predicted the occurrence of overall AKI. In contrast, age (P = 0.85), gender (P = 0.25), BMI (P = 0.25), systolic blood pressure (0.28), steady-state renal function (eGFR P = 0.98), medical therapy (ACE-I P = 0.10; ARB P = 0.11; diuretics P = 0.49) and the volume of CM (P = 0.96) all were not suitable to predict the occurrence of AKI. When restricting the regression analysis to creatinine-blind AKI cases, occurring between day 1 and day 2, only delta PENK remained significantly associated with the occurrence of late AKI (OR per standard deviation increase: 3.13, 95% CI: 1.02-9.64, P = 0.04). 
| DISCUSSION
In this investigation, we examined the potential of PENK levels at baseline and serially thereafter to predict the occurrence of contrast-induced AKI in 111 hospitalized CKD patients. We report five major findings. First, baseline PENK levels drawn before the administration of CM were significantly correlated to steady-state renal function. Second, baseline PENK and baseline creatinine levels were similar in AKI and no-AKI patients and failed to predict the subsequent occurrence of contrast-induced AKI. The similarity of baseline serum creatinine in AKI and no-AKI patients is probably due to the selective inclusion of CKD patients into our study. As CKD is the most common risk factor for CIN, 12,13 studies enrolling patients irrespective of prior renal function frequently describe higher baseline creatinine levels in patients subsequently developing CIN. 10, 11 Third, PENK levels increased significantly after the administration of CM in patients developing contrast-induced AKI, while remaining stable in no-AKI patients. Consequently, day 1 PENK levels after CM administration were significantly higher in AKI compared to no-AKI patients. Forth, Day 1 PENK and serum creatinine levels detected overall AKI with similar accuracy. Fifth, delta PENK achieved the best diagnostic accuracy for the detection of overall AKI and creatinine-blind AKI, providing AUCs of 0.92 and 0.94, respectively. Our results extend and corroborate previous studies investigating the potential clinical applicability of PENK. The correlation of baseline PENK with concurrently drawn serum creatinine values has been described before. 10, 15, 19 This link between baseline PENK levels and steady-state renal function is further highlighted by the strong association of published PENK levels with steady-state renal function described across a wide range of populations, which appear to show a near linear increase of PENK with decreasing renal function (ie, healthy participants: eGFR 91 mL/min, PENK 46 pmol/L 9 ; cardiac surgery: eGFR 75 ml/min, PENK 85 pmol/L 11 ; acute heart failure: eGFR 56 ml/min, PENK 97 pmol/L 19 ; CKD current study: eGFR 45 ml/min, PENK 126 pmol/L). This link between chronic renal function and baseline PENK levels might also explain the apparent disagreement between our results and two recent studies investigating patients undergoing cardiac surgery. 10, 11 These studies found baseline PENK levels drawn before surgery to be increased in patients suffering from postsurgical AKI. 10, 11 However, both studies showed pronounced differences in the prevalence of CKD between AKI and no-AKI patients, with CKD being four times more common in AKI compared to the no-AKI patients. We therefore believe that the increased baseline PENK levels observed for AKI patients mainly represent impaired chronic renal function, rather than an early AKI signal. This interpretation is backed by Mossanen and co-workers, who found the diagnostic accuracy of baseline PENK levels to decrease after the exclusion of patients with known CKD and subsequently elevated baseline PENK levels. 11 Importantly, both studies found preoperative PENK levels to not improve the prediction of AKI over baseline serum creatinine.
10,11
Baseline PENK In this CKD cohort, the vast majority of patients displayed PENK levels above the previously suggested universal cut-off value of 100 pmol/L but did not develop subsequent AKI. This observation might at least partially be caused by PENK accumulation in CKD patients and the strong association of PENK with chronic renal dysfunction. It highlights the need for further studies to establish clinically applicable cut-off values in CKD patients.
The early PENK increase in patients experiencing AKI compared to the stable values in no-AKI patients observed in the current study suggests delta PENK as powerful marker for the early detection of AKI. Importantly, delta PENK was strongly associated with overall AKI and retained its diagnostic accuracy for the detection of creatinine-blind AKI, thereby accelerating the clinical diagnosis of creatinine-blind AKI by 24 hours. The diagnostic potential of early PENK changes was also observed by Shah and coworkers, who assessed 92 patients undergoing cardiac surgery 10 and also found delta PENK to best predict late AKI.
Despite the lack of causative therapeutic interventions currently available for the treatment of AKI, the early detection of AKI is of vital importance and offers a window of opportunity for the initiation of supportive measures (ie, volume management, maintenance of adequate blood pressure, avoidance of nephrotoxins) to reduce the duration of the AKI episode. 20, 21 The enormous potential of early supportive therapy was recently highlighted in a study assessing the impact of electronic automated AKI alerts. This study showed a convincing sevenfold decrease in the requirement of renal replacement therapy and a 2.4-fold decrease in mortality in patients receiving supportive therapy on the day of the alert compared to patients receiving delayed supportive therapy (day 1 or later). 22 Of note, this intervention was based on the review of serial creatinine measurements, and the additional 24-hour window of opportunity provided delta PENK could potentially provide even bigger benefits. 23 Potential limitations of the current study merit consideration. First, our study has a moderate number of patients and only few developed AKI. However, the strong correlation of baseline PENK with stable serum creatinine values observed in our study is in line with various other publications. 10, 15, 19 We are therefore confident, that our baseline PENK results will apply to other populations. Nevertheless, due to the low number of AKI cases observed in our cohort, we cannot exclude the possibility of a Type II error for the serial sampling part of our study. Second, we did not include the any urine output criteria into the definition of contrast-induced AKI. However, while recent data suggest, that including urine output criteria into the AKI definition might increase the AKI incidence, 24 most previously published studies assessing the predictive potential of AKI biomarkers in the non-ICU setting, also opted to exclude the urine output criteria for AKI diagnosis 10, 15, 25 as measuring urine output in a non-ICU setting is tedious and error prone. When routinely measuring urine output via a urinary catheter, any additional information obtained by measuring urine output needs to be carefully weighed against the potential morbidity, mortality, and healthcare expenditure associated with catheter-associated urinary tract infections. 26 Third, a general limitation for the comparison of a novel marker of interest for the prediction of AKI with creatinine is that this is principally biased by the fact that creatinine is a constituent of the AKI definition.
| CONCLUSION
Delta PENK levels may improve the early detection of contrast-induced AKI over serial creatinine sampling. Delta PENK may accelerate the detection of creatinine-blind AKI by 24 hours.
